Breast Cancer Res Treat (2017) 165:467–468 DOI 10.1007/s10549-017-4351-0 LETTER TO THE EDITOR Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB? 1 1 1 • • • Vasileios Askoxylakis David P. Kodack Gino B. Ferraro Rakesh K. Jain Received: 27 May 2017 / Accepted: 19 June 2017 / Published online: 22 June 2017 Springer Science+Business Media, LLC 2017 We read with great interest the ﬁndings by Lewis-Phillips incidence of extracranial occurrence, whereas CNS relap- et al. on the preclinical delivery of trastuzumab in brain ses do not appear to be affected. Together, these data metastases . The authors compared directly the uptake of suggest that trastuzumab does not directly cause BM, but radiolabeled trastuzumab in isogenic tumors implanted in fails to prevent recurrence in the brain. the brain or the mammary fat pad (MFP) of immune- The efﬁcacy of trastuzumab against established BM competent mice. Interestingly, nearly equivalent Zr- appears to be limited, in comparison to its efﬁcacy against trastuzumab uptake at both sites was reported. Efﬁcacy extracranial disease. Although retrospective clinical anal- analysis of the murine analog of trastuzumab (muMab yses suggest that trastuzumab may prolong survival
Breast Cancer Research and Treatment – Springer Journals
Published: Jun 22, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera